Thursday, April 18, 2024 4/18/2024

Targeting AXL to overcome resistance to taxanes and platinum-based therapy in castrate resistant and neuroendocrine prostate cancer

Award Number: R21CA245595
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY The success of prostate cancer (PCa) therapies with the goal of improving overall survival principally hinges on our ability to treat metastatic disease as shown by the sharp decline of 5-year survival rates from 100% in localized and regional disease to <30% in metastatic disease. Docetaxel and platinum-based drugs have been the first-line chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) for many years, however, the survival benefit of docetaxel and platinum-based drugs is modest and patients inevitably develop resistance. Therefore, improving the efficacy of docetaxel and carboplatin and preventing or reversing docetaxel and carboplatin resistance of mCRPC, especially those in the bone, would have a large impact on improving overall survival of men with mCRPC. The receptor tyrosine kinase AXL has been identified as a key molecule in resistance to both conventional chemotherapy and targeted therapies. In PCa, AXL is an essential regulator of cell proliferation, migration, invasion and docetaxel resistance. In addition, AXL inhibition sensitized mCRPC cells to docetaxel when grown at the subcutaneous site, suggesting that AXL inhibition may be an effective strategy to reverse docetaxel resistance in mCRPC. We propose to determine whether blocking AXL signaling using a novel soluble AXL (sAXL) decoy receptor will inhibit mCPRC growth in the bone, which produce the greatest morbidity due to fractures, bone pain, and spinal cord compression, as a single agent and whether this decoy receptor will sensitize cancer cells to docetaxel or carboplatin when used in combination. This decoy receptor has shown excellent efficacy with little toxicity in inhibiting tumor growth and reverse drug resistance and currently being evaluated in clinical trials in other cancer types. To enhance rapid translation of our findings to the clinic, we will use the most clinically relevant bone models of mCRPC generated by direct implantation of patient-derived xenograft (PDX) tissues into mice. We will select 4 out of the 12 available castration-resistant PDX models to test sAXL therapy in this study. Moreover, we will identify biomarkers that predict responses to this inhibitor by comparing the gene expression profiles of tumors responding to treatments to those that do not at RNA and protein levels. Our study represents the first attempt to evaluate whether inhibition of tyrosine kinase receptor AXL in mCRPC will be effective in suppressing tumor growth in the bone. If our small preclinical scale study demonstrates efficacy of sAXL as a single agent or in synergy with docetaxel and carboplatin in treating mCRPC, we will have compelling evidence for testing of sAXL therapy in a much larger study using all 12 castration-resistant PDX lines. Our long-term goal is to provide strong rationale for a phase 2 clinical trial of sAXL therapy in men with mCRPC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	000	2	4/28/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $184,312 )
2021	2021	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	000	2	1/15/2021	NON-COMPETING CONTINUATION	$184,312
														Subtotal = $184,312

Issue Date FY: 2020 ( Subtotal = $221,808 )
2020	2020	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	000	1	2/20/2020	NEW	$221,808
														Subtotal = $221,808

Grand Total All Awards = $406,120

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting AXL to overcome resistance to taxanes and platinum-based therapy in castrate resistant and neuroendocrine prostate cancer

Award Number: R21CA245595

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer